Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.
You may also be interested in...
Only top-line data were released by Pfizer, and the safety of abrocitinib, like other JAK inhibitors, could remain an issue.
CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model.
The new indication represents the third one for Sanofi/Regeneron's IL-4/IL-13 inhibitor, after atopic dermatitis and moderate to severe asthma.